Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CervoMed ( (CRVO) ).
CervoMed Inc., a clinical-stage company developing treatments for neurologic disorders, will present detailed safety and efficacy results from its RewinD-LB Phase 2b trial at the International Lewy Body Dementia Conference in Amsterdam. The trial focuses on neflamapimod, a potential therapy for dementia with Lewy bodies, with topline results expected in December 2024. This development is highly anticipated given the current lack of approved therapies for this condition, drawing significant interest from the scientific community.
For an in-depth examination of CRVO stock, go to TipRanks’ Stock Analysis page.